Biogen, Incorporated

Point Therapeutics, Inc.

Ziopharm Oncology, Inc.

University of Michigan

Other

Dana-farber-cancer Institute Inc.

Astellas US LLC

Barbara P Wallner

Glenn T Miller

R Blake Pepinsky

Margaret D Rosa

Philip B Komarnitsky

Catherine A Hession

Sharlene Adams

Jeffrey L Garwin

Kevin D Cooper

William Bachovchin

Barry Jones

Jeffrey L Browning

John C Amedio, Jr

Timothy Alan Springer

Michael L Dustin

Kuo-Sen Huang

Richard Tizard

Robert Mattaliano

Daniel G Schindler

Disclosed herein are crystalline compounds of formula (I) 

Salts of isophosphoramide mustard and analogs thereof

Organic arsenical compounds are useful to inhibit angiogenesis in a variety of disease conditions.

Method for controlling angiogenesis in animals

The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-1 or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-1 in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-1 and another therapeutic agent.

Combination therapy with organic arsenicals

Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.

Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction

A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

Anti-tumor agents

Methods, compositions, and devices for stimulating the number and/or differentiation of hematopoietic cells in vitro are provided. The methods involve contacting the hematopoietic cells with an inhibitor of dipeptidyl peptidase (DPIV) in the absence of exogenously provided cytokines.

Stimulation of hematopoietic cells in vitro

A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.

Regulation of substrate activity

Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I wherein m is an integer between 0 and 10, inclusive; A and Aare L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, Aand C, and between Aand N are peptide bonds; and each Xand Xis, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.

Hematopoietic stimulation

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

Growing community of inventors

Cambridge, MA, United States of America

Barbara P Wallner